Alimta

... Abbott urged to subsidise asbestos disease drug.

14/04/2005.

ABC News Online News Home Top Stories Just In World Australia/Local Business Politics Weather Sport Health Arts Sci-Tech Environment Rural Indigenous Offbeat In-Depth Forums Services Help/Site Map Programs - RADIO - AM Back.

Briefing Business Report Corresp.

Report Go Asia Pacific NewsRadio PM Sunday Profile World Today - TV - 7.30 Report Asia Pacific Focus Aust.

Story Bus.

Breakfast Foreign Corresp.

Four Corners Inside Business Insiders Landline Lateline Stateline Print Email Last Update: Thursday, April 14, 2005.

7:16am (AEST) Abbott urged to subsidise asbestos disease drug Federal Health Minister Tony Abbott is under pressure to expand the Pharmaceutical Benefits Scheme (PBS) to include a drug that helps alleviate suffering in people with mesothelioma.

The president of the Asbestos Diseases Society in Perth, Robert Vojakovic, says the drug He says he has written to Mr Abbott reminding him of a promise he made in the lead up to the last federal election.

"Last year when he w...

... US News : Big Pharma Results Seen Lackluster Due to Withdrawals, Limited Pipeline, ( Breaking News,Kerala news, India News,Us,UK,Kerala Shopping,Onam Special, Kerala Greetings,Kerala Dress,Kerala Recipes,Hindi Tutor,Malayalam tutor, VCD's, DVD's,Bharatnatyam, Yoga, indian music,indian dance, kerala dance, kerala music, kerala recipes RSS FEEDS NEWS DOWNLOADS DIRECTORY POLL SHOPPING CALLING CARDS GIFTS CRICKET DO YOU KNOW?

HOME NEWS SEARCH INDIA SHOP SHOPPING MOVIE CRICKET FORUMS BUSINESS News India Pakistan Cricket Live Scorecard Home US US ; Big Pharma Results Seen Lackluster Due to Withdrawals, Limited Pipeline: 40 minutes Ago [US News] NEW YORK - U.S.

drug makers are expected to report a lackluster first quarter, reflecting an ongoing struggle with product withdrawals, a dearth of new drugs in the pipeline and increased competition from generics.

Profits at most major drug makers will be driven by the companies' ability to hold down costs, rather than by bringing in more revenue from existing products, said C.J.

Sylvester, an analyst with Banc of America Securities.

"We believe the industry is in the latter stages of a cyclical downturn in (research and development) productivity," Sylvester said in a research note.

Two exceptions could be Wyeth Laboratories Ltd.

and Eli Lilly & Co., Sylvester said.

Wyeth is experiencing strong sales of its anti-inflammatory drug Enbrel, its vaccine Prevn...

... Ambrx Appoints Dr.

August Watanabe to Board of Directors Ambrx Appoints Dr.

August Watanabe to Board of Directors SAN DIEGO, April 13 /PRNewswire/ - Ambrx, Inc., today announced the appointment of August M.

Watanabe, M.D.

to its Board of Directors.

Dr.

Watanabe was formerly a senior executive at Eli Lilly & Company, where he occupied the positions of Executive Vice President of Science and Technology, President of Lilly Research Laboratories and a member of the Board of Directors.

During his tenure the company became recognized as having one the strongest new drug pipelines in the industry, including Forteo(R) and Xigris(R) and the recently launched drugs From 1971 to 1990, Dr.

Watanabe was a full time faculty member at Indiana University School of Medicine.

He was professor and chairman of the department of medicine at the medical school from 1983 to 1990.

Dr.

Watanabe was also formerly a director of the American Heart Association and the American College of Cardiology, and a member of the American Society of Clinical Investigation and the Association of American Physicians.

He served for six years as chairman of the Science and Technology Section of the Pharmaceutical Research and Manufacturing Association of America (PhRMA).

Dr.

Watanabe is a partner in Twilight Venture Partners LLC and serves as Volunteer Chairman of BioCrossroads, Indiana's leading public-private life science network.

He als...